Walleye Capital
PTGX icon

Walleye Capital’s Protagonist Therapeutics PTGX Stock Holding History

Walleye Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$539K Sell
4,400
-26,400
-86% -$2.76M ﹤0.01% 2653
2026
Q1 		$3.25M Buy
30,800
+7,200
+31% +$637K 0.01% 1081
2025
Q4 		$2.06M Buy
+23,600
New +$1.93M 0.01% 1852
2023
Q3 		– Sell
-2,100
Closed -$58K – 5239
2023
Q2 		$58K Sell
2,100
-3,200
-60% -$80.1K ﹤0.01% 3609
2023
Q1 		$122K Buy
+5,300
New +$89K ﹤0.01% 2818

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Walleye Capital's PTGX Position: Q2 2026 in Review

Walleye Capital opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 1 share worth $123. The stake represents ﹤0.01% of the portfolio and ranks #4638 among its holdings. This is a return to the name: Walleye Capital previously reported a position in PTGX as recently as Q3 2024.

Walleye Capital first reported a position in PTGX in Q3 2021 and has held it in 13 quarters since. The position peaked at $5.72M in Q4 2022. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Walleye Capital held 1 share of Protagonist Therapeutics worth $123 as of Q2 2026.
  • Protagonist Therapeutics was a new Walleye Capital position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4638 holding.
  • Walleye Capital first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 13 quarters since.
  • Walleye Capital's Protagonist Therapeutics position peaked at $5.72M in Q4 2022.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.